interceptor vet. 2.3 mg tabletti
elanco gmbh - milbemycin oxime - tabletti - 2.3 mg - milbemysiinioksiimi
interceptor vet. 5.75 mg tabletti
elanco gmbh - milbemycin oxime - tabletti - 5.75 mg - milbemysiinioksiimi
interceptor vet. 11.5 mg tabletti
elanco gmbh - milbemycin oxime - tabletti - 11.5 mg - milbemysiinioksiimi
interceptor vet. 23 mg tabletti
elanco gmbh - milbemycin oxime - tabletti - 23 mg - milbemysiinioksiimi
plavix
sanofi winthrop industrie - klopidogreelin vetysulfaatti - stroke; peripheral vascular diseases; atrial fibrillation; myocardial infarction; acute coronary syndrome - antitromboottiset aineet - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-st-segment-elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st-segment-elevation acute myocardial infarction, in combination with asa in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. in patients with moderate to high-risk transient ischemic attack (tia) or minor ischemic stroke (is)clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. ehkäisy aterotromboottisten ja tromboembolisten tapahtumien eteisen fibrillationin aikuisten eteisvärinäpotilailla, joilla on vähintään yksi verisuonitapahtumiin kuten tapahtumia, eivät sovellu hoito vitamiini-k-antagonistit ja joilla on vähäinen verenvuodon riski, klopidogreeli on tarkoitettu yhdistelmänä asa: n ehkäisyyn aterotromboottisten ja tromboembolisten tapahtumien, kuten aivoinfarktin.
welpan vet. 15 mg/ml + 5 mg/ml oraalisuspensio
vetoquinol s.a. - febantel, pyrantel embonate - oraalisuspensio - 15 mg/ml + 5 mg/ml - pyranteeli
prazitel plus 50 mg / 144 mg / 150 mg tabletti
chanelle pharmaceuticals manufacturing limited - febantel, praziquantel, pyrantel embonate - tabletti - 50 mg / 144 mg / 150 mg - pratsikvanteeli
veloxa vet 150 mg / 144 mg / 50 mg purutabletti
lavet pharmaceuticals ltd. - febantel, praziquantel, pyrantel embonate - purutabletti - 150 mg / 144 mg / 50 mg - pratsikvanteeli
veloxa vet 525 mg / 504 mg / 175 mg purutabletti
lavet pharmaceuticals ltd. - febantel, praziquantel, pyrantel embonate - purutabletti - 525 mg / 504 mg / 175 mg - pratsikvanteeli
dronbits 150 mg / 144 mg / 50 mg tabletti
vetoquinol s.a. - praziquantel, febantel, pyrantel embonate - tabletti - 150 mg / 144 mg / 50 mg - pratsikvanteeli